Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

This Phase 2 clinical trial tests HM15275 — a new investigational weekly injection being evaluated for weight loss — in obese or overweight adults without type 2 diabetes over 36 weeks. Participants are randomized to one of five arms (different doses of HM15275 or placebo) to evaluate how well the drug reduces body weight and how safe and tolerable it is across different dosing levels. Adults aged 18–75 (19–75 in Korea) with a BMI of 30–50 (or 27–30 with at least one weight-related health condition) whose weight has been stable within the past 3 months are eligible; people with diabetes, prior obesity surgery, a history of pancreatitis, or certain heart conditions are excluded. Participation involves weekly subcutaneous (under-the-skin) injections for 36 weeks, a 6-week screening period, and a 4-week safety follow-up. This summary was prepared as patient-facing educational content using AI assistance.